Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Case 7: - Where did her period go?
Published online by Cambridge University Press: 03 April 2024
Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Summary
Which antipsychotic medications are most commonly associated with causing hyperprolactinemia?
Keywords
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential Psychopharmacology , pp. 109 - 132Publisher: Cambridge University PressPrint publication year: 2024
References
Byerly, M, Suppes, T, Tran, QV, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007; 27:639–61CrossRefGoogle ScholarPubMed
Holt, RI, Peveler, RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf) 2011; 74:141–7CrossRefGoogle ScholarPubMed
Johnsen, E, Kroken, RA, Abaza, M, et al. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol 2008; 28:686–90CrossRefGoogle ScholarPubMed
Keck, PE, Jr., McElroy, SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003; 12:655–62CrossRefGoogle ScholarPubMed
Melkersson, K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005; 66:761–7CrossRefGoogle ScholarPubMed
Melmed, S, Casanueva, FF, Hoffman, AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273–88CrossRefGoogle ScholarPubMed
Meng, M, Li, W, Zhang, S, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry 2015; 27:4–17Google ScholarPubMed
Meyer, JM, Stahl, SM. The Clinical Use of Antipsychotic Plasma Levels. Cambridge: Cambridge University Press, 2021CrossRefGoogle Scholar
Miyamoto, BE, Galecki, M, Francois, D. Guidelines for antipsychotic-induced hyperprolactinemia. Psychiatr Ann 2015; 45:266–72CrossRefGoogle Scholar
Petty, RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999; 35 Suppl.:S67–73CrossRefGoogle ScholarPubMed
Stahl, SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5. Cambridge: Cambridge University Press, 2021CrossRefGoogle Scholar
Turrone, P, Kapur, S, Seeman, MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159:133–5CrossRefGoogle ScholarPubMed
Volavka, J, Czobor, P, Cooper, TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004; 65:57–61CrossRefGoogle ScholarPubMed
Wang, ZM, Xiang, YT, An, FR, et al. Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China. Perspect Psychiatr Care 2014; 50:257–63CrossRefGoogle ScholarPubMed